K-ACT Actalyke Clotting Test Tubes that are used in the: ACTALYKE XL ACTIVATED CLOTTING TIME ANALYZER, and ACTALYKE MINI ACTIVATED CLOTTING TIME TEST SYSTEM.
Class I - DangerousWhat Should You Do?
- Check if you have this product: Catalog Number: K-ACT Lot Number: 1-19-K-ACT and 2-19-K-ACT
- Do not eat it: Even if it looks and smells fine, do not consume this product.
- Throw it away or return it: You can return the product to the store for a full refund.
- Seek medical attention if needed: If you've consumed this product and feel unwell, contact your doctor immediately.
- Report problems: Report any issues to the FDA's Safety Reporting Portal.
⚠️ Emergency: If you experience severe symptoms after consuming this product, call 911 or Poison Control at 1-800-222-1222.
Recall Details
- Company:
- Helena Laboratories, Corp.
- Reason for Recall:
- Due to complaints received associated with cracked/split test tube caps.
- Classification:
- Class I - Dangerous
Dangerous or defective products that predictably could cause serious health problems or death.
- Status:
- ongoing
Product Information
Full Description:
K-ACT Actalyke Clotting Test Tubes that are used in the: ACTALYKE XL ACTIVATED CLOTTING TIME ANALYZER, and ACTALYKE MINI ACTIVATED CLOTTING TIME TEST SYSTEM.
Product Codes/Lot Numbers:
Catalog Number: K-ACT Lot Number: 1-19-K-ACT and 2-19-K-ACT
Official Source
Always verify recall information with the official FDA source:
View on FDA.govFDA Recall Number: Z-0635-2021
Related Recalls
Serrated Blade Applicator Kit (12 Sample), REF: 552687, For use with the Spife Nexus system, Contents: 30 Blade Applicators. used in invitro diagnostics
Helena Laboratories
Packaging for a serrated blade applicator kit (12 Sample) may contain a serrated blade applicator (18 sample). This results in a characteristic pattern of missed or light samples on the gel, leading to incorrect or no result, or delay in result.
V8 Immunodisplacement Kit REF 1803
Helena Laboratories
Due to microbial growth causing interference with interpretation.
Intermittent potential for shorter than expected clot times.